Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

To mark the 10-year anniversary of the drug’s approval, Astra Zeneca launched the first DTC campaign for Tagrisso.

TAGRISSO demonstrated efficacy in patients with measurable central nervous system (CNS) lesions at baseline. March 31, 2017 07:00 AM Eastern Daylight Time.

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFR m NSCLC after chemoradiotherapy. SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFR m NSCLC with high levels of ...

Tagrisso appears to short-circuit this excessive growth. The new trial involved 682 patients with stages IB, II or IIIA non-small cell lung cancers (NSCLC). About 85% of lung cancers are NSCLCs.

AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically ...